why choose us

First received: November 29, 2022

Clinical Trial: Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Clonal Cytopenia of Undetermined Significance

Study Type: INTERVENTIONAL


Official Title: A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS)

Brief Summary: This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS).CCUS is a blood condition defined by a decrease in blood cells.Blood cells are composed of either red blood cells, white blood cells, or platelets.In patients with CCUS, blood counts have been low for a long period of time.Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop.The combination of genetic…

Read more